



Genetic Evaluation of the Child With Intellectual Disability or Global Developmental Delay: Clinical Report

Lance H. Rodan, MD,^{1,2} Joan Stoler, MD, FAAP,¹ Emily Chen, MD, PhD,³ Timothy Geleske, MD, FAAP,⁴ and the Council on Genetics

Genetic neurodevelopmental disorders are common in the pediatric population, and establishing a specific diagnosis early provides multiple benefits including prognostication, surveillance for disorder-related complications, accurate recurrence risk, and specific management. This report provides an approach to the genetic evaluation of developmental delay/intellectual disability for the general pediatrician. When possible, genetic testing should be selected by phenotype, and typical distinguishing clinical features to facilitate this are presented. If a specific disorder or group of disorders cannot be ascertained by phenotype, an agnostic (or hypothesis-free) approach is utilized. Recommendations are provided for this agnostic approach based on diagnostic yield and also practical considerations such as test complexity and impact on management. The general guidance in this report for genetic testing does not preclude further evaluation by relevant subspecialists as necessary, including neurologists, developmental pediatricians, and clinical geneticists.

INTRODUCTION

Global developmental delay (GDD)/intellectual disability (ID) has an estimated global prevalence of 1% to 3%.¹ Further, in pediatric primary care, neurodevelopmental disorders are the most common chronic medical condition, with a combined prevalence of approximately 17%.² Neurodevelopmental disorders have a considerable impact at individual, family, and societal levels. Global developmental delay is defined in the *Diagnostic and Statistical Manual of Mental Disorders, 5th Edition* (DSM-5) as the failure to meet expected developmental milestones in several areas of intellectual functioning in an individual younger than 5 years who

abstract



¹Division of Genetics and Genomics, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts; ²Department of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts; ³Department of Genetics, Kaiser Permanente, San Francisco, California; and ⁴Northwestern University Feinberg School of Medicine, Chicago, Illinois

Drs Rodan and Stoler prepared and revised the manuscript. Drs Chen and Geleske revised the manuscript.

FINANCIAL/CONFLICT OF INTEREST DISCLOSURE: The authors have indicated they have no potential conflicts of interest to disclose. This document is copyrighted and is property of the American Academy of Pediatrics and its Board of Directors. All authors have filed conflict of interest statements with the American Academy of Pediatrics. Any conflicts have been resolved through a process approved by the Board of Directors. The American Academy of Pediatrics has neither solicited nor accepted any commercial involvement in the development of the content of this publication. Clinical reports from the American Academy of Pediatrics benefit from expertise and resources of liaisons and internal (AAP) and external reviewers. However, clinical reports from the American Academy of Pediatrics may not reflect the views of the liaisons or the organizations or government agencies that they represent. The guidance in this report does not indicate an exclusive course of treatment or serve as a standard of medical care. Variations, taking into account individual circumstances, may be appropriate. All clinical reports from the American Academy of Pediatrics automatically expire 5 years after publication unless reaffirmed, revised, or retired at or before that time.

To cite: Rodan LH, Stoler J, Chen E, et al; American Academy of Pediatrics, Council on Genetics. Genetic Evaluation of the Child With Intellectual Disability or Global Developmental Delay: Clinical Report. *Pediatrics*. 2025;156(1):e2025072219